News Releases Year: - Any -2021202020192018201720162015201420132012 Items per page 102550 07/22/13 Summary ToggleClearside Biomedical, Inc. Announces Appointment of Gerald D. Cagle, Ph.D. to Board of Directors Release3c1cc8f4-cce0-4807-acf3-82e929cab221_1981130.pdf 10.4 KB 05/01/13 Summary ToggleClearside Biomedical to Present Research on Proprietary Retinal Therapeutics Platform at 2013 ARVO Meeting Releaseaeba802b-9108-442a-9c5b-bfe39a2365ed_1981131.pdf 14.2 KB 03/04/13 Summary ToggleClearside Biomedical, Inc. Names Stephen H. Lang Vice President, Commercial Operations Release7cd7f6e3-306b-4c3c-8e03-0c23f4915fd3_1981132.pdf 10.9 KB 02/25/13 Summary ToggleSanten Pharmaceutical Co., Ltd. and Clearside Biomedical, Inc. Enter into Financing and Research Collaboration Agreements for Posterior Ocular Disease Releaseacf22348-72f8-4d22-9505-a14239c63af8_1981135.pdf 17.9 KB 02/25/13 Summary ToggleClearside Biomedical Names Rafael V. Andino Vice President, Product Development Release2184c45f-9ce7-4166-ad4b-3abf1768d697_1981134.pdf 10.3 KB 01/10/13 Summary ToggleClearside Biomedical Announces Plans for Clinical Testing of CLS1001 (Triamcinolone Acetonide) Suprachoroidal Injectable Suspension for the Treatment of Uveitis Releasef0757699-d36f-43fe-9338-7a74457ccfb3_1981140.pdf 9.2 KB 11/06/12 Summary ToggleClearside Biomedical Announces First Successful Human Dosing – November 6, 2012 Releaseb72f6291-3086-4e62-93c3-2ccf0414eadd_1981141.pdf 13.7 KB 10/29/12 Summary ToggleClearside Biomedical Names Charles Deignan Chief Financial Officer Releaseff0901e3-c4ae-4ae6-aa9c-1d3a839ea42c_1981143.pdf 9.1 KB 01/25/12 Summary ToggleClearside Biomedical Launched with Pipeline and Technology Focused on Drugs Delivered to the Back of the Eye Release4e0e3fd0-1d7d-4dc4-8bcf-7d1d0f280237_1981144.pdf 17.1 KB Pagination First page First Previous page Page 16 Page 17 Page 18 Current page 19
